With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
One day after two trials indicated remdesivir offers therapeutic benefit in patients hospitalized for COVID-19 infections, Gilead Sciences Inc.’s first quarter earnings call was dominated by discussion of the antiviral, including how the company might build a commercial business for treating the novel coronavirus.
Gilead did not update its revenue guidance for 2020 on the 30 April call, and said it saw roughly $200m...
After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.
Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.
Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.
